Tech Company Financing Transactions
Cyllene Therapeutics Funding Round
Cyllene Therapeutics, operating out of Paris, secured $5.6 million from private investors.
Transaction Overview
Company Name
Announced On
7/13/2023
Transaction Type
Venture Equity
Amount
$5,620,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to finance clinical development of EG110A and advance other pipeline products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
13 rue Watt
Paris, 75013
France
Paris, 75013
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Cyllene Therapeutics is a French biotechnology company that is pioneering a new approach called pinpoint gene therapy. Developing next generation DNA medicines to provide safe, efficacious, and affordable therapies to patients with severe localized chronic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philippe Chambon
Chief Marketing Officer
Cornelia Molkenteller
Chief Operating Officer
Samuel Salot
Chief Scientific Officer
Alberto Epstein
Co-Founder
Pierre Denys
Co-Founder
François Giuliano
Co-Founder
Charles Joussain
VP - Bus. Development
Mikael Contrastin
VP - R & D
Teddy Jégu
VP - R & D
Astrid Valles-Sanchez
Browse more venture capital transactions:
Prev: 7/13/2023: Zluri venture capital transaction
Next: 7/13/2023: Mattilda venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs